BRPI0918970A2 - algoritmo para projeto de inibidores irreversíveis - Google Patents
algoritmo para projeto de inibidores irreversíveisInfo
- Publication number
- BRPI0918970A2 BRPI0918970A2 BRPI0918970A BRPI0918970A BRPI0918970A2 BR PI0918970 A2 BRPI0918970 A2 BR PI0918970A2 BR PI0918970 A BRPI0918970 A BR PI0918970A BR PI0918970 A BRPI0918970 A BR PI0918970A BR PI0918970 A2 BRPI0918970 A2 BR PI0918970A2
- Authority
- BR
- Brazil
- Prior art keywords
- algorithm
- irreversible inhibitor
- inhibitor design
- design
- irreversible
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/203—Unsaturated compounds containing keto groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C49/205—Methyl-vinyl ketone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Computing Systems (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Evolutionary Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9478208P | 2008-09-05 | 2008-09-05 | |
| PCT/US2009/056025 WO2010028236A1 (en) | 2008-09-05 | 2009-09-04 | Algorithm for designing irreversible inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0918970A2 true BRPI0918970A2 (pt) | 2019-09-24 |
Family
ID=41797504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0918970A BRPI0918970A2 (pt) | 2008-09-05 | 2009-09-04 | algoritmo para projeto de inibidores irreversíveis |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100185419A1 (pt) |
| EP (1) | EP2352827A4 (pt) |
| JP (2) | JP2012501654A (pt) |
| KR (1) | KR101341876B1 (pt) |
| CN (2) | CN102405284B (pt) |
| AU (1) | AU2009289602B2 (pt) |
| BR (1) | BRPI0918970A2 (pt) |
| CA (1) | CA2735937A1 (pt) |
| IL (1) | IL211553A0 (pt) |
| MX (1) | MX2011002484A (pt) |
| MY (1) | MY156789A (pt) |
| NZ (2) | NZ621143A (pt) |
| RU (2) | RU2014150660A (pt) |
| SG (1) | SG193859A1 (pt) |
| WO (1) | WO2010028236A1 (pt) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8809273B2 (en) | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
| EP2152079A4 (en) | 2007-06-04 | 2011-03-09 | Avila Therapeutics Inc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| MX2010012703A (es) | 2008-05-21 | 2010-12-21 | Ariad Pharma Inc | Derivados fosforosos como inhibidores de cinasa. |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| IN2012DN02534A (pt) | 2009-09-16 | 2015-08-28 | Avila Therapeutics Inc | |
| US20110269244A1 (en) | 2009-12-30 | 2011-11-03 | Petter Russell C | Ligand-directed covalent modification of protein |
| CA3007787C (en) | 2010-06-03 | 2020-03-10 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
| CA2822556A1 (en) | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
| US8951964B2 (en) | 2010-12-30 | 2015-02-10 | Abbvie Inc. | Phenanthridine macrocyclic hepatitis C serine protease inhibitors |
| BR112013027734A2 (pt) | 2011-05-04 | 2017-08-08 | Ariad Pharma Inc | compostos para a inibição de proliferação celular em cânceres impulsionados pelo egfr, método e composição farmacêutica |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| BR112014000653A2 (pt) | 2011-07-13 | 2017-02-14 | Pharmacyclics Inc | inibidores de tirosina quinase de bruton |
| EP2736895B1 (en) | 2011-07-27 | 2016-01-06 | Astrazeneca AB | 2-(2,4,5-substituted-anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
| CA2856291C (en) | 2011-11-17 | 2020-08-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| AU2013204563B2 (en) * | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| DK2872491T3 (da) | 2012-07-11 | 2021-08-09 | Blueprint Medicines Corp | Inhibitorer af fibroblastvækstfaktorreceptoren |
| CA2879570A1 (en) | 2012-07-24 | 2014-01-30 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| MX2015006168A (es) | 2012-11-15 | 2015-08-10 | Pharmacyclics Inc | Compuestos de pirrolopirimidina como inhibidores de quinasas. |
| US9321786B2 (en) | 2013-03-15 | 2016-04-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| EP3943087A1 (en) | 2013-03-15 | 2022-01-26 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| CA2908098A1 (en) | 2013-03-15 | 2014-09-25 | Celgene Avilomics Research, Inc. | Mk2 inhibitors and uses thereof |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| SG11201506764WA (en) | 2013-04-25 | 2015-09-29 | Beigene Ltd | Fused heterocyclic compounds as protein kinase inhibitors |
| CN103387510B (zh) * | 2013-08-08 | 2015-09-09 | 苏州永健生物医药有限公司 | 一种β-氨基-alpha-羟基环丁基丁酰胺盐酸盐的合成方法 |
| JP6623353B2 (ja) | 2013-09-13 | 2019-12-25 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗ｐｄ−１抗体並びにその治療及び診断のための使用 |
| KR20160062103A (ko) | 2013-09-30 | 2016-06-01 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 키나제의 억제제 |
| BR112016008849B8 (pt) | 2013-10-25 | 2022-09-06 | Blueprint Medicines Corp | Compostos ou sais farmaceuticamente aceitáveis dos mesmos, uso dos referidos compostos e composições farmacêuticas |
| WO2015083028A1 (en) | 2013-12-05 | 2015-06-11 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| MA38393B1 (fr) * | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
| EP3119910A4 (en) | 2014-03-20 | 2018-02-21 | Pharmacyclics LLC | Phospholipase c gamma 2 and resistance associated mutations |
| WO2015196144A2 (en) * | 2014-06-20 | 2015-12-23 | England Pamela M | Androgen receptor antagonists |
| KR102003754B1 (ko) | 2014-07-03 | 2019-07-25 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
| CN106999494A (zh) | 2014-08-01 | 2017-08-01 | 药品循环有限公司 | 布鲁顿酪氨酸激酶的抑制剂 |
| JP6558828B2 (ja) * | 2015-08-21 | 2019-08-14 | 株式会社ゲノム創薬研究所 | 予測方法及び該予測方法を用いるタンパク−タンパク相互作用のインターフェースを阻害する阻害剤の候補となり得る化合物の設計方法 |
| CN106407739B (zh) * | 2016-04-22 | 2019-02-22 | 三峡大学 | 小分子共价抑制剂计算机筛选方法及其在筛选s-腺苷甲硫氨酸脱羧酶共价抑制剂的应用 |
| NZ749997A (en) | 2016-07-05 | 2022-11-25 | Beigene Ltd | Combination of a pd-l antagonist and a raf inhibitor for treating cancer |
| KR102604975B1 (ko) | 2016-08-16 | 2023-11-24 | 베이진 스위찰랜드 게엠베하 | (s)-7-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)-4,5,6,7-테트라-하이드로피라졸로 [1,5-a] 피리미딘-3-카르복스아미드의 제조 및 그 용도 |
| EP3500299B1 (en) | 2016-08-19 | 2023-12-13 | BeiGene Switzerland GmbH | Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer |
| WO2018049233A1 (en) | 2016-09-08 | 2018-03-15 | Nicolas Stransky | Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors |
| JP2019529419A (ja) | 2016-09-19 | 2019-10-17 | エムイーアイ ファーマ，インク． | 併用療法 |
| WO2018112315A1 (en) * | 2016-12-16 | 2018-06-21 | Northwestern University | Systems and methods for developing covalent inhibitor libraries for screening using virtual docking and experimental approaches |
| WO2018137681A1 (en) | 2017-01-25 | 2018-08-02 | Beigene, Ltd. | Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof |
| KR102757960B1 (ko) | 2017-06-26 | 2025-01-22 | 베이진 엘티디 | 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료 |
| CN110997677A (zh) | 2017-08-12 | 2020-04-10 | 百济神州有限公司 | 具有改进的双重选择性的Btk抑制剂 |
| US10426424B2 (en) | 2017-11-21 | 2019-10-01 | General Electric Company | System and method for generating and performing imaging protocol simulations |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| CN113645976A (zh) | 2019-03-29 | 2021-11-12 | 阿斯利康(瑞典)有限公司 | 用于治疗非小细胞肺癌的奧希替尼 |
| US20220249491A1 (en) | 2019-06-10 | 2022-08-11 | Beigene Switzerland Gmbh | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor |
| WO2021055749A1 (en) * | 2019-09-19 | 2021-03-25 | Totus Medicines Inc. | Therapeutic conjugates |
| WO2023027279A1 (ko) * | 2021-08-27 | 2023-03-02 | 디어젠 주식회사 | 화학구조 내부 원자의 키나아제 결합여부 예측 방법 |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5856116A (en) * | 1994-06-17 | 1999-01-05 | Vertex Pharmaceuticals, Incorporated | Crystal structure and mutants of interleukin-1 beta converting enzyme |
| US5756466A (en) * | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5760041A (en) * | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| HU228446B1 (en) * | 1996-04-12 | 2013-03-28 | Warner Lambert Co | Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof |
| US5867236A (en) * | 1996-05-21 | 1999-02-02 | Rainbow Displays, Inc. | Construction and sealing of tiled, flat-panel displays |
| US6686350B1 (en) * | 1996-07-25 | 2004-02-03 | Biogen, Inc. | Cell adhesion inhibitors |
| ES2285735T3 (es) * | 1996-07-25 | 2007-11-16 | Biogen Idec Inc | Modelo molecular para inhibidores de vla-4. |
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6162613A (en) * | 1998-02-18 | 2000-12-19 | Vertex Pharmaceuticals, Inc. | Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases |
| US7383135B1 (en) * | 1998-05-04 | 2008-06-03 | Vertex Pharmaceuticals Incorporated | Methods of designing inhibitors for JNK kinases |
| US6919178B2 (en) * | 2000-11-21 | 2005-07-19 | Sunesis Pharmaceuticals, Inc. | Extended tethering approach for rapid identification of ligands |
| US6335155B1 (en) * | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
| US6288082B1 (en) * | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US6569876B1 (en) * | 1999-06-17 | 2003-05-27 | John C. Cheronis | Method and structure for inhibiting activity of serine elastases |
| US6420364B1 (en) * | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
| RU2165458C1 (ru) * | 1999-10-07 | 2001-04-20 | Гайнуллина Эра Тазетдиновна | Способ определения необратимых ингибиторов холинэстеразы в воде и водных экстрактах |
| AU2001236720A1 (en) * | 2000-02-05 | 2001-08-14 | Bemis, Guy | Compositions useful as inhibitors of erk |
| US6384051B1 (en) * | 2000-03-13 | 2002-05-07 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
| CA2417500C (en) * | 2000-07-28 | 2008-11-18 | Georgetown University Medical Center | Erbb-2 selective small molecule kinase inhibitors |
| HUP0400639A3 (en) * | 2000-12-21 | 2010-03-29 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them |
| US7235576B1 (en) * | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| IL144583A0 (en) * | 2001-07-26 | 2002-05-23 | Peptor Ltd | Chimeric protein kinase inhibitors |
| IL161409A0 (en) * | 2001-11-21 | 2004-09-27 | Sunesis Pharmaceuticals Inc | Methods for ligand discovery |
| CA2472580A1 (en) * | 2002-01-07 | 2003-07-17 | Sequoia Pharmaceuticals | Broad spectrum inhibitors |
| US7202033B2 (en) * | 2002-03-21 | 2007-04-10 | Sunesis Pharmaceuticals, Inc. | Identification of kinase inhibitors |
| MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| EP1375517A1 (en) * | 2002-06-21 | 2004-01-02 | Smithkline Beecham Corporation | Structure of a glucocorticoid receptor ligand binding domain comprising an expanded binding pocket and methods employing same |
| GB0221169D0 (en) * | 2002-09-12 | 2002-10-23 | Univ Bath | Crystal |
| PE20040945A1 (es) * | 2003-02-05 | 2004-12-14 | Warner Lambert Co | Preparacion de quinazolinas substituidas |
| UY28213A1 (es) * | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| EP1610808A4 (en) * | 2003-03-26 | 2011-04-06 | Sudhir Paul | COVALENT BINDING OF LIGANDS TO NUCLEOPHILIC PROTEINS UNDER GUIDANCE BY NONCOVALENT BINDING |
| US7687506B2 (en) * | 2003-04-11 | 2010-03-30 | The Regents Of The University Of California | Selective serine/threonine kinase inhibitors |
| WO2004113274A2 (en) * | 2003-05-20 | 2004-12-29 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
| EP1648516A2 (en) * | 2003-08-01 | 2006-04-26 | Wyeth Holdings Corporation | Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer |
| GB0321710D0 (en) * | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
| WO2005043118A2 (en) * | 2003-10-27 | 2005-05-12 | Vertex Pharmaceuticals Incorporated | Drug discovery method |
| US7932382B2 (en) * | 2004-01-16 | 2011-04-26 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
| WO2005115145A2 (en) * | 2004-05-20 | 2005-12-08 | Wyeth | Quinone substituted quinazoline and quinoline kinase inhibitors |
| US20060079494A1 (en) * | 2004-09-27 | 2006-04-13 | Santi Daniel V | Specific kinase inhibitors |
| KR20080002826A (ko) * | 2005-04-14 | 2008-01-04 | 와이어쓰 | 게피티니브 내성 환자에서의 표피 성장 인자 수용체（ｅｇｆｒ） 키나제 억제제의 용도 |
| TW200734327A (en) * | 2005-11-03 | 2007-09-16 | Vertex Pharma | Aminopyrimidines useful as kinase inhibitors |
| EA018573B1 (ru) * | 2006-09-22 | 2013-09-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| EP2152079A4 (en) * | 2007-06-04 | 2011-03-09 | Avila Therapeutics Inc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| EP2214486A4 (en) * | 2007-10-19 | 2011-03-09 | Avila Therapeutics Inc | HETEROARYL COMPOUNDS AND ITS USES |
| TW200932255A (en) * | 2007-12-21 | 2009-08-01 | Avila Therapeutics Inc | HCV protease inhibitors and uses thereof |
| IN2012DN02534A (pt) * | 2009-09-16 | 2015-08-28 | Avila Therapeutics Inc | |
| US20110269244A1 (en) * | 2009-12-30 | 2011-11-03 | Petter Russell C | Ligand-directed covalent modification of protein |
-
2009
- 2009-09-04 MY MYPI2011000991A patent/MY156789A/en unknown
- 2009-09-04 US US12/554,433 patent/US20100185419A1/en not_active Abandoned
- 2009-09-04 SG SG2013067178A patent/SG193859A1/en unknown
- 2009-09-04 CN CN200980144148.XA patent/CN102405284B/zh not_active Expired - Fee Related
- 2009-09-04 WO PCT/US2009/056025 patent/WO2010028236A1/en not_active Ceased
- 2009-09-04 NZ NZ621143A patent/NZ621143A/en not_active IP Right Cessation
- 2009-09-04 JP JP2011526225A patent/JP2012501654A/ja active Pending
- 2009-09-04 CA CA2735937A patent/CA2735937A1/en not_active Abandoned
- 2009-09-04 NZ NZ603495A patent/NZ603495A/en not_active IP Right Cessation
- 2009-09-04 CN CN201510983154.1A patent/CN105574346A/zh active Pending
- 2009-09-04 RU RU2014150660/10A patent/RU2014150660A/ru not_active Application Discontinuation
- 2009-09-04 AU AU2009289602A patent/AU2009289602B2/en not_active Ceased
- 2009-09-04 EP EP09812276.5A patent/EP2352827A4/en not_active Withdrawn
- 2009-09-04 KR KR1020117007889A patent/KR101341876B1/ko not_active Expired - Fee Related
- 2009-09-04 MX MX2011002484A patent/MX2011002484A/es unknown
- 2009-09-04 RU RU2011108531/10A patent/RU2542963C2/ru not_active IP Right Cessation
- 2009-09-04 BR BRPI0918970A patent/BRPI0918970A2/pt not_active IP Right Cessation
-
2011
- 2011-03-03 IL IL211553A patent/IL211553A0/en not_active IP Right Cessation
-
2014
- 2014-12-03 JP JP2014245335A patent/JP2015062428A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN102405284B (zh) | 2016-01-20 |
| US20100185419A1 (en) | 2010-07-22 |
| RU2542963C2 (ru) | 2015-02-27 |
| WO2010028236A1 (en) | 2010-03-11 |
| AU2009289602A1 (en) | 2010-03-11 |
| HK1169139A1 (zh) | 2013-01-18 |
| KR101341876B1 (ko) | 2013-12-20 |
| CN105574346A (zh) | 2016-05-11 |
| MY156789A (en) | 2016-03-31 |
| EP2352827A1 (en) | 2011-08-10 |
| JP2012501654A (ja) | 2012-01-26 |
| NZ621143A (en) | 2016-08-26 |
| SG193859A1 (en) | 2013-10-30 |
| MX2011002484A (es) | 2011-09-26 |
| JP2015062428A (ja) | 2015-04-09 |
| RU2011108531A (ru) | 2012-10-10 |
| NZ603495A (en) | 2014-05-30 |
| EP2352827A4 (en) | 2016-07-20 |
| CA2735937A1 (en) | 2010-03-11 |
| AU2009289602B2 (en) | 2014-02-13 |
| IL211553A0 (en) | 2011-05-31 |
| CN102405284A (zh) | 2012-04-04 |
| RU2014150660A (ru) | 2015-07-20 |
| KR20110084169A (ko) | 2011-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0918970A2 (pt) | algoritmo para projeto de inibidores irreversíveis | |
| CY2020023I1 (el) | Αναστολεiς βητα-λακταμασων | |
| CY2017016I1 (el) | Αναστολεις πρωτεασωματος | |
| EP2305306A4 (en) | NEURO INVASION INHIBITOR | |
| SMT201600081B (it) | Inibitore di bromodominio di benzodiazepina | |
| BRPI0917808A2 (pt) | inibidores de cmet | |
| SMT201600104B (it) | Inibitore di bromodominio benzodiazepinico | |
| DK2421825T3 (da) | Azetidinyldiamider som monoacylglycerollipase-inhibitorer | |
| CR20120576A (es) | Inhibidores de pirazolil quinazolina cinasa | |
| BRPI0919548A2 (pt) | pacote para inserto | |
| BRPI0918564A2 (pt) | inibidores | |
| BRPI0806898A2 (pt) | Inibidores de mek | |
| BR112012001070A2 (pt) | inibidores de ativação de complementos | |
| BR112012006411A2 (pt) | óculos sem hastes para prender nas orelhas | |
| DK2240506T3 (da) | IAP inhibitorer | |
| EP2177529A4 (en) | NEW SECRETASE HEMMER | |
| BRPI0918966A2 (pt) | inibidores de protease | |
| ATE522533T1 (de) | Pyrazolopyrimidinonkinaseinhibitor | |
| SMT201500178B (it) | Inibitori di nf-kb | |
| ES1070784Y (es) | Cerramiento para pista de padel | |
| BRPI0919073A2 (pt) | inibidores de protease | |
| FI20075320A0 (fi) | Uusia käyttökelpoisia inhibiittoreita | |
| ES1069687Y (es) | Embalaje para aparato electrodomestico | |
| ES1065835Y (es) | Caperuza para cetreria | |
| ES1070148Y (es) | Macolla para barrotes mejorada |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: CELGENE AVILOMICS RESEARCH, INC. (US) |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |